The DOI matches its Crossref record.
Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects.
Abstract
Obesity is commonly associated with elevated plasma free fatty acid (FFA) levels, as well as with insulin resistance and hyperinsulinemia, two important cardiovascular risk factors. What causes insulin resistance and hyperinsulinemia in obesity remains uncertain. Here, we have tested the hypothesis that FFAs are the link between obesity and insulin resistance/hyperinsulinemia and that, therefore, lowering of chronically elevated plasma FFA levels would improve insulin resistance/hyperinsulinemia and glucose tolerance in obese nondiabetic and diabetic subjects. Acipimox (250 mg), a long-acting antilipolytic drug, or placebo was given overnight (at 7:00 P.M., 1:00 A.M., 7:00 A.M.) to 9 lean control subjects, 13 obese nondiabetic subjects, 10 obese subjects with impaired glucose tolerance, and 11 patients with type 2 diabetes. Euglycemic-hyperinsulinemic clamps and oral glucose tolerance tests (75 g) were performed on separate mornings after overnight Acipimox or placebo treatment. In the three obese study groups, Acipimox lowered fasting levels of plasma FFAs (by 60-70%) and plasma insulin (by approximately 50%). Insulin-stimulated glucose uptake during euglycemic-hyperinsulinemic clamping was more than twofold higher after Acipimox than after placebo. Areas under the glucose and insulin curves during oral glucose tolerance testing were both approximately 30% lower after Acipimox administration than after placebo. We conclude that lowering of elevated plasma FFA levels can reduce insulin resistance/hyperinsulinemia and improve oral glucose tolerance in lean and obese nondiabetic subjects and in obese patients with type 2 diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conversely, reduction of plasma FFA concentration in insulin resistant individuals, for example, type 2 diabetic subjects, augments insulin-stimulated glucose disposal in skeletal muscle [69–72], and the improvement in insulin sensitivity is closely associated with a reduction in intramyocellular FACoA concentration [69].”
From Pathogenesis of insulin resistance in skeletal muscle (2010) · cites this paper as [72]
In the citing paper
“Further evidence linking fatty acids to insulin sensitivity comes from clinical studies showing that pharmacological inhibition of lipolysis decreases fatty acid levels and rapidly enhances insulin sen-sitivity in diabetic and nondiabetic, lean and obese subjects (48,49).”
From Insulin sensitivity: Modulation by nutrients and inflammation (2008) · cites this paper as [48]
Citations
Cited by
Sorted by citations
Items 401–431 of 431
Endocrine regulation of lipid mobilization in human obesity
Verboven (2017) · Research Publications (Maastricht University) · doi:10.26481/dis.20170703kv
Immune cell phenotype and function : impact of type 2 diabetes, obesity, and exercise
Barry, J. (2018) · cIRcle (University of British Columbia) · doi:10.14288/1.0362080
“Conversely, when plasma FFAs are reduced by acipimox (long-acting antilipolytic drug) in insulin-resistant individuals, there is increased insulin-stimulated glucose disposal in skeletal muscle [56-58].”
BackgroundO’Leary, M. F. (2018) · University of Birmingham Institutional Research Archive (University of Birmingham)
Mechanisms Mediating Anti-Inflammatory Effects of Delta-Tocotrienol
Mena, L. T. (2018) · ThinkTech (Texas Tech University)
The effects of short-term low-carbohydrate and ketogenic interventions on cardiometabolic health
Myette‐Côté, É. (2019) · cIRcle (University of British Columbia) · doi:10.14288/1.0378478
“Infusing NEFA has also been shown to impair insulin sensitivity through an increase in intracellular lipid metabolites, causing the insulin-receptor signaling cascade to diminish [96].”
BackgroundInfluentialPhysical Activity and Endurance Training Modalities: Evidences and Perspectives
Malatesta, D., Fanari, P., Salvadori, A., & Lanzi, S. (2020) · Springer eBooks · doi:10.1007/978-3-030-32274-8_1
The effect of lipids on glucoregulatory hormone actions
Grueter, E., & Alicia, C. (2006)
Williams, K. J., Horton, E. S., & Siraj, E. S. (2020) · Diabetes Care · doi:10.2337/dci20-0041
“Moreover, the Boden laboratory found that lowering of chronically elevated plasma NEFAs in obese patients with either impaired glucose tolerance or frank diabetes was able to substantially, though only partially, improve sensitivity to the glucose-lowering actions of insulin (10).”
BackgroundEffects of Exercise on Factors Regulating Adipose Tissue Expandability
Ludzki, A. C. (2020) · Deep Blue (University of Michigan)
Moran, M. (2021) · International Journal of Complementary & Alternative Medicine · doi:10.15406/ijcam.2021.14.00526
Characterization of the crosstalk between immunity and metabolism in Drosophila melanogaster model
Davoodi, S. (2021) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3-0bhx-5r30
Concepts of Insulin Resistance
Bloomgarden, Z. T. (2005) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2005.3.212
Rathee, N. S. (2015) · Journal of Mathematics and System Science · doi:10.17265/2159-5291/2015.06.004
Reasner, C. A. (2006) · Fundamental and clinical cardiology · doi:10.3109/9781420019667.011
Dirks, M. L., Jameson, T. S. O., Andrews, R. C., Dunlop, M. V., Abdelrahman, D. R., Murton, A. J., Wall, B. T., & Stephens, F. B. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.10.561668
“We used four times daily administration of 250 mg acipimox, a nicotinic acid analogue that inhibits adipose tissue lipolysis for around 6 hours and improves insulin sensitivity [16-18], so that muscle NEFA uptake would be reduced throughout the entire immobilisation period.”
BackgroundMethodKostadinov, N. (2024) · MEDIS – International Journal of Medical Sciences and Research · doi:10.35120/medisij030231k
Nutrient Involvement in Insulin Secretion and Blood Glucose Variability
Kanazawa, Y. (2024) · Nippon Eiyo Shokuryo Gakkaishi · doi:10.4327/jsnfs.77.345
Higgs, B. C., Willis, B.-A. N., Goodwin, V. A. M., Ung, G., McMillen, C. D., Burick, E. K., Barroso, J., & Pienkos, J. A. (2025) · Journal of Organometallic Chemistry · doi:10.1016/j.jorganchem.2025.123932
Role of MAP4K4 Signaling in Adipocyte and Macrophage Derived Inflammation: A Dissertation
Tesz, G. J. (2008) · eScholarship@UMassChan · doi:10.13028/521b-rp68
Tan, H. Y. (2014) · The University of Queensland · doi:10.14264/uql.2015.99
The role of NF-kB activation I fatty acid-induced insulin resistance in skeletal muscle
Hommelberg, P. P. H. (2011) · Research Publications (Maastricht University) · doi:10.26481/dis.20110225ph
de Oliveira, R. F., Jácome‐Santos, H., Bernardes, S. S., Ferreira, L. A. Q., Freitas, T. C., Silva, M. D. S., Leme, F. D. O. P., Barcelos, L. S., Diniz, M. G., de Avelar, G. F., et al. (2026) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2026.113427
Self-citationPyrimidine and NAD salvage pathways : unexpected allies in the maintenance of genome stability
Silveira, S. C. (2018) · theses.fr (ABES) · doi:10.70675/d8951764z7ae2z4d5eza2e1z0b24bea9f901
Le rôle de l'érythroferrone dans la régulation du métabolisme du fer
Sardo, U. (2020) · theses.fr (ABES) · doi:10.70675/d03e67aczc44bz4af9z8fa1zef080668f44f
HealthMarkers: Clinical and Metabolic Biomarker Calculation Toolkit
Suleman, S. (2026) · CRAN: Contributed Packages · doi:10.32614/cran.package.healthmarkers
BindingDB Entry 50027562: Nicotinic acid receptor agonists.
BindingDB (2010) · UC San Diego · doi:10.7270/q27d2tz5
Mitochondrial adaptations in insulin resistant muscle
Broek, N. N. (2010) · TU/e Research Portal · doi:10.6100/ir684831
Metadata
- Authors
- Santomauro, A. T., Boden, G., Silva, M. E., Rocha, D. M., Santos, R. F., Ursich, M. J., Strassmann, P. G., & Wajchenberg, B. L.
- Affiliations
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 1999-09-01
- Volume
- 48
- Issue
- 9
- Pages
- 1836-1841
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2007405015
- Cited by
- 431
- References
- 0
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 7 · 2023: 9 · 2022: 7 · 2021: 11 · 2020: 20 · 2019: 10 · 2018: 17 · 2017: 18 · 2016: 10 · 2015: 17 · 2014: 18 · 2013: 20 · 2012: 24
- FWCI
- 9.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ag007988-10, 5r01aa010221-03)
- National Institute on Alcohol Abuse and Alcoholism (R01-AA-10221)
- National Institute on Aging (R01-AG07988)
- National Center for Research Resources (M01RR000349, RR-00349)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diet, Metabolism, and Disease
- Keywords
- acipimox, free fatty acids, insulin resistance, hyperinsulinemia, glucose tolerance, obesity, type 2 diabetes, impaired glucose tolerance, insulin-stimulated glucose uptake, hyperinsulinemic-euglycemic clamp, oral glucose tolerance test
- MeSH terms
- Adult, Hypolipidemic Agents, Basal Metabolism, Diabetes Mellitus, Fatty Acids, Nonesterified, Female, Glucose Tolerance Test, Humans, Insulin Resistance, Male, Obesity, Oxidation-Reduction, Pyrazines, Glucose Clamp Technique
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
